Darzalex Faspro (D-VRd) PDUFA Date (Johnson & Johnson)
FDA PDUFA decision date for Darzalex Faspro (D-VRd) is January 27, 2026. Developed by Johnson & Johnson. Indication: Newly diagnosed multiple myeloma (transplant eligible). Current status: Approved.
Indication
Newly diagnosed multiple myeloma (transplant eligible)
Regulatory details
- Company: Johnson & Johnson
- Therapeutic area: Oncology
- Application type: sBLA
- Review type: Priority
- PDUFA date: 2026-01-27
- Outcome: Approved